GH Research PLC (GHRS)
11.99
0.00 (0.00%)
USD |
NASDAQ |
May 09, 16:00
12.00
0.00 (0.00%)
Pre-Market: 20:00
GH Research Cash from Operations (Quarterly): -9.596M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -9.596M |
| December 31, 2023 | -8.085M |
| September 30, 2023 | -10.34M |
| June 30, 2023 | -8.026M |
| March 31, 2023 | -6.885M |
| December 31, 2022 | -6.867M |
| September 30, 2022 | -8.045M |
| June 30, 2022 | -5.286M |
| March 31, 2022 | -6.001M |
| Date | Value |
|---|---|
| December 31, 2021 | -3.758M |
| September 30, 2021 | -9.213M |
| June 30, 2021 | -1.225M |
| March 31, 2021 | -1.087M |
| December 31, 2020 | -0.149M |
| September 30, 2020 | -0.077M |
| June 30, 2020 | -0.002M |
| March 31, 2020 | -0.102M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-10.34M
Minimum
Sep 2023
-0.002M
Maximum
Jun 2020
-4.985M
Average
-6.001M
Median
Mar 2022
Cash from Operations (Quarterly) Benchmarks
| Amarin Corp PLC | -12.60M |
| Jazz Pharmaceuticals PLC | 267.23M |
| Prothena Corp PLC | -73.05M |
| Iterum Therapeutics PLC | -12.84M |
| Mural Oncology PLC | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 8.788M |
| Cash from Financing (Quarterly) | -0.071M |
| Free Cash Flow | -36.14M |
| Free Cash Flow Per Share (Quarterly) | -0.1847 |
| Free Cash Flow Yield | -5.79% |